Communicating the importance of managed care pharmacy is a key part of AMCP’s work. Using AMCP policies as a basis for their work, AMCP staff and volunteers provide comments, analysis and testimony to Congress and other federal and state agencies on how proposed regulations and laws impact managed care pharmacy and the patients we serve.
Archives
5/14/2013
»AMCP Provides Comments to the California Assembly Committee on Appropriations Regarding Imposing Additional Requirements for Health Plans or Pharmacy Benefit Manager Step Therapy Programs
5/08/2013
» AMCP Provides Comments To The Texas House of Representatives Public Health Committee Regarding Legislation Placing Unecessary Burdens on the Substitution of Biosimilars
» AMCP Provides Comments and Requests Colorado Governor Hickenlooper Veto State Legislation Adversely Affecting Uniform Prior Authorization of Prescription Drugs
5/03/2013
»AMCP Provides Comments to the Senate Health, Education, Labor, and Pensions Committee Regarding Draft Legislation Addressing Pharmaceutical Compounding
5/01/2013
» AMCP Sends Letter of Opposition to the Nevada State Assembly Commerce and Labor Committee Regarding Outpatient Oral Chemotherapy Agents
4/30/2013
» AMCP Sends Letter of Opposition to the California State Assembly Health Committee Regarding Imposing Additional Requirements for Health Plans or Pharmacy Benefit Manager Step Therapy Programs
4/22/2013
»AMCP Sends Letter of Opposition to the New Hampshire House of Representatives Health, Human Services, and Elderly Affairs Committee Regarding Uniform Prior Authorization of Prescription Drugs
4/16/2013
»AMCP Summary of a CMS Proposed Rule Outlining MLR Requirements for Medicare Part D and MA plans
» AMCP Submits Comments to a CMS Proposed Rule Outlining MLR Requirements for Medicare
Part D and MA plans
4/10/2013
» AMCP Sends Letter of Opposition to the Oregon State Senate Committee on Health Care and Human Services Regarding Unnecessary Burdens Placed on Biosimilar Substitutions
4/05/2013
»AMCP Sends Letter of Opposition to the California State Senate Committee on Business, Professions and Economic Development Regarding Placing Unnecessary Burdens on Biosimilar Substitutions
4/01/2013
»AMCP Sends Letter of Support to the Massachusetts Joint Committee on Public Health Regarding Collaborative Drug Therapy Management
3/26/2013
» AMCP Requests Governor Dalrymple Veto Senate bill 2190, Regarding the Substitution of Biosimilars
» AMCP Sends Letter of Opposition to the Nevada Senate Committee on Commerce, Labor, and Energy Regarding Outpatient Oral Chemotherapy Agents
3/20/2013
»AMCP Sends Letter of Opposition to the North Dakota House of Representatives Regarding Placing Unnecessary Burdens on Biosimilars
3/19/2013
» AMCP Sends Senate Letter Suggesting Efforts Towards Reducing the Federal Budget Deficit
» AMCP Sends Joint Letter to the Senate Opposing Restrictionson Government Employees Who Can Attend Meetings and Conferences
3/18/2013
» AMCP Sends House of Representatives Letter Suggesting Efforts for Reducing the Federal Budget Deficit
3/14/2013
» AMCP Sends Letter of Opposition to Maryland's Health and Government Operations Committee Regarding the Substitution of Biosimilars
3/12/2013
» AMCP Sends Letter of Support to Senator Klobuchar Regarding the Prohibition of Generic Exclusion Agreements
» AMCP Sends Letter of Opposition to Maryland's Senate Finance Committee Regarding Specialty Drugs
3/04/2013
» AMCP Sends Comment Letter to Texas House of Representatives Regarding Uniform Prior Authorization
2/28/2013
» AMCP Comments to CMS on 2014 Draft Call Letter
2/28/2013
» AMCP Sends Letter of Opposition to Oregon's General Assembly Regarding Limits on Biosimilars Substitution
2/26/2013
» AMCP Sends Letter of Opposition to Maryland's House of Delegates Regarding Specialty Drugs Legislation
2/21/2013
» HHS Finalizes Rule for Prescription Drug Benefit Design under Essential Health Benefits to Implement Affordable Care Act Provisions and Clarifies Preventive Coverage for Certain OTC Items
2/11/2013
» AMCP Sends Comment Letter to Senate Majority Leader Reid and Minority Leader McConnell on Deficit Reduction
» AMCP Sends Comment Letter to Speaker Boehner and Ranking Member Pelosi on Deficit Reduction
2/06/2013
» HHS Issues Proposal for Accommodations for Religious Organizations that Object to Provision of Contraception
2/01/2013
» Director of Health and Human Services, Kathleen Sebelius, Details Impact of Sequester in Letter to Senator Mikulski
1/28/2013
» AMCP Sends Letter to Virginia State Senator Martin in Opposition to Biosimilars Substitution Legislation
1/09/2013
» AMCP Sends Letter to Massachusetts Gov. Deval Patrick on Chemotherapy Parity Bill
1/04/2013
» AMCP Comments on Health Care Quality in the Exchanges
12/20/2012
» AMCP Comments on HHS’ Proposed Rule on Essential Health Benefits
12/6/2012
» AMCP Summary of Proposed Rule for Establishment of the Multi-State Plan Program for the Affordable Insurance Exchanges
11/30/2012
» AMCP Letter Sent to Congressional Leaders and Obama Administration Suggesting Ways to Reduce Federal Spending on Health Care
11/26/2012
» AMCP Summary of Three Proposed Rules to Implement Affordable Care Act, Including Prescription Drug Coverage under Essential Health Benefits
11/14/2012
» Pharmacists’ Commitment to Patient Safety and Compounding Quality
10/01/2012
» AMCP request for immediate clarification of HCR requirements
9/28/2012
» AMCP comments on Draft Guidance for Industry on Generic Drug User Fee Act
9/10/2012
» National Quality Forum Measure Application Partnership
9/04/2012
» AMCP Letter to Governor Jerry Brown regarding cost sharing/chemotherapy agents
8/20/2012
» AMCP letter to Louisiana Board of Pharmacy on Pharmacist Licensing Regulations
8/9/2012
» Pharmacy Stakeholder Letter Opposing Proposed Congressional Elimination of AHRQ Funding
7/23/2012
» AMCP letter to Senate Finance Committee members addressing fraud in the Medicare and Medicaid programs
7/20/2012
» AMCP comments to CMS on additional guidance related to improving drug utilization review controls in Part D
6/15/2012
» AMCP cosigns a letter submitted to the American Medical Association (AMA) regarding Resolution 218 and 240 - Pharmacist Prescribing and Resolution 235 - Opposition of FDA's Rx to OTC Paradigm Shift
6/13/2012
» AMCP comments to HHS on the advanced notice of proposed rulemaking (ANPRM) regarding certain preventive services under the Affordable Care Act
6/12/2012
» AMCP White Paper on Medicare and Medicaid Program Integrity
6/8/2012
» AMCP Cosigns a Letter to Senate Health, Energy, Labor, and Pensions Committee on Drug Shortages
» AMCP Cosigns a Letter to House Energy and Commerce Committee on Drug Shortages
6/1/2012
» AMCP cosigns a letter submitted to the American Medical Asssociation (AMA) regarding Resolution 218 - Pharmacist Prescribing and Resolution 235 - Opposition of FDA's Rx to OTC Paradigm Shift
5/22/2012
» AMCP comments to the FDA on the draft guidances relating to the development of biosimilar products
5/21/2012
» AMCP letter to Senate Homeland Security Committee on Federal Travel Restrictions
» AMCP signed on with members of the Partnership for Safe Medicines to address concerns regarding drug importation
5/17/2012
» AMCP letter to Congress on Drug Importation Amendment
5/14/2012
» AMCP comments to the FDA on direct-to-consumer (DTC) television advertisements
» AMCP comments to the FDA on issues that may result in a prescription drug or biological product shortage
5/7/2012
» AMCP Joins group letter to House Energy and Commerce on Efforts to Reduce Drug Shortages
» AMCP comments to CMS on Stage 2 of the Electronic Health Record Incentive Program
» AMCP provides input to HHS Office of the Surgeon General of the United States Public Health Service on prescription medication adherence
» AMCP comments to the FDA on conditions of safe use to expand which drug products can be considered nonprescription
4/24/2012
» AMCP joins sign on letter supporting Senate drug shortages language
4/23/2012
» AMCP sends final comments to Senate HELP on PDUFA reauthorization
4/16/2012
» AMCP summary of the CMS Final Rule to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for 2013
4/12/2012
» AMCP comments to the National Quality Forum (NQF) Measures Application Partnership (MAP) final report to HHS on measuring healthcare quality for the dual eligible population
» AMCP provides comments to the FDA on Q&As regarding implementation of the Biologics Price Competition and Innovation Act of 2009 (BPCI Act)
» AMCP provides comments to the FDA on quality considerations in demonstrating biosimilarity to a reference protein product.
4/11/2012
» AMCP Summary of Calendar Year (CY) 2013 Call Letter: Items of Importance to Managed Care Pharmacy
4/9/2012
» AMCP provides comments to Senate HELP Committee on the reauthorization of the Prescription Drug User Fee Act
» AMCP letter to House Judiciary Subcommittee on H.R. 1946, the "Preserving Our Hometown Independent Pharmacy Act of 2011"
4/6/2012
» AMCP Joins group letter to Senate HELP Committee on Drug Shortages
3/26/2012
» AMCP letter to House Energy and Commerce Committee on PDUFA reauthorization
» AMCP letter to Senate Committee on Health, Education, Labor, and Pensions on PDUFA reauthorization
» AMCP comments to the FDA on communications and activities related to off-label uses of marketed products and use of products not yet legally marketed
» AMCP comments to the FDA on the Draft Guidance for Industry; responding to unsolicited requests for off-label information about prescription drugs and medical devices
3/23/2012
» AMCP letter to Senate Health, Education, Labor, and Pensions Committee on drug shortages
» AMCP letter to House Energy and Commerce Committee on drug shortages
» AMCP letter to National Governors Association
3/22/2012
» Marissa Schlaifer, R.Ph., AMCP's Director of Pharmacy Affairs testifimony to the FDA on behalf of the Academy on Using Innovative Technologies and Other Conditions of Safe Use To Expand Which Drug Products Can Be Considered Nonprescription (Testimony Presentation Slides)
3/16/2012
» AMCP joins nine pharmacy associations to comment to the American Academy of Family Physicians (AAFP) on their recently released position paper Pharmacists
3/14/2012
» AMCP comments to the National Committee for Quality Assurance (NCQA) on proposed changes to the 2013 Healthcare Effectiveness Data and Information Set (HEDIS) Measures.
» AMCP comments to the FDA on the Healthcare Professional Survey of Prescription Drug Promotion
» AMCP comments to the Patient-Centered Outcomes Research Institute (PCORI) on its Draft National Priorities for Research and Research Agenda, Version 1
3/2/2012
» AMCP comments to CMS on the draft Advance Notice of Changes for Calendar Year 2013 in the 2013 Call Letter
2/22/2012
» HHS response to AMCP's comment letter on essential health benefits associated with the affordable insurance Exchanges
» HHS response to AMCP's comment letter on coverage of preventive services under the Affordable Care Act (ACA)
2/13/2012
» AMCP comments to the FDA on New Drug; Revision of Postmarketing Reporting Requirements - Discontinuance
2/7/2012
» AMCP summary of the CMS Proposed Rule on Medicaid Program Covered Outpatient Drugs
2/3/2012
» AMCP comments to the Patient-Centered Primary Care Collaborative (PCPCC) on the proposed medication management guidelines
1/31/2012
» AMCP comments to CMS on proposed changes to the Part D Reporting Requirements for Contract Year 2013
» AMCP comments to HHS on the Essential Health Benefits Bulletin issued by the Center for Consumer Information and Insurance Oversight (CCIIO) on December 16, 2011.
1/20/2012
» AMCP comments to NQF on Patient Outcomes: All Cause Readmissions Expedited Review 2011: A Consensus Report
1/19/2012
» AMCP comments on NQF Measure Application Partnership (MAP) Pre-Rulemaking Report
1/13/2012
» AMCP comments to the Centers for Medicare & Medicaid Services (CMS) on enhancements to the Part C and Part D plan ratings
1/5/2012
» The Department of Labor responds to AMCP on coverage of preventive services under the Affordable Care Act (ACA)
1/4/2012
» AMCP comments to the Food and Drug Administration (FDA) on the proposed recommendations for enactment of the Generic Drug User Fee Act (GDUFA)